What are the KDIGO recommendations for lipid-lowering treatment in adults with CKD?
The KDIGO recommendations for lipid-lowering treatment in adults with CKD include ruling out remediable causes of secondary dyslipidemia, establishing the indication of treatment (YES or NO) and selecting the agent and dose, and following a fire-and-forget strategy where LDL-C is not measured unless the results would alter treatment. If a statin is indicated, the nephrologist should select a dose of a statin that is available in her/his country and has been tested for safety in people with CKD. Furthermore, contemporary practice and other clinical practice guidelines emphasize the use of targets for LDL-C, which requires repeated measurements of LDL-C and treatment escalation with higher doses of statin or initiation of combination lipid-lowering therapy if the LDL-C target is not met.